RT Journal Article
SR Electronic
T1 Prospective study of machine learning for identification of high-risk COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.21.24303159
DO 10.1101/2024.02.21.24303159
A1 Frausto-Avila, Mateo
A1 León-Montiel, Roberto de J.
A1 Quiroz-Juárez, Mario A.
A1 U’Ren, Alfred B.
YR 2024
UL http://medrxiv.org/content/early/2024/02/23/2024.02.21.24303159.abstract
AB The Coronavirus Disease 2019 (COVID-19) pandemic constituted a public health crisis with a devastating effect in terms of its death toll and effects on the world economy. Notably, machine learning methods have played a pivotal role in devising novel technological solutions designed to tackle challenges brought forth by this pandemic. In particular, tools for the rapid identification of high-risk COVID-19 patients have been developed to aid in the effective allocation of hospital resources and for containing the spread of the virus. A comprehensive validation of such intelligent technological approaches is needed to ascertain their clinical utility; importantly, it may help develop future strategies for efficient patient classification to be used in future viral outbreaks. Here we present a prospective study to evaluate the performance of state-of-the-art machine-learning models proposed in PloS one 16, e0257234 (2021), which we developed for the identification of high-risk COVID-19 patients across four identified clinical stages. The model relies on artificial neural networks trained with historical patient data from Mexico. To assess their predictive capabilities across the six, registered, epidemiological waves of COVID-19 infection in Mexico, we measure the accuracy within each wave without retraining the neural networks. We then compare their performance against neural networks trained with cumulative historical data up to the end of each wave. Our findings indicate that models trained using early historical data exhibit strong predictive capabilities, which allows us to accurately identify high-risk patients in subsequent epidemiological waves—under clearly varying vaccination, prevalent viral strain, and medical treatment conditions. These results show that artificial intelligence-based methods for patient classification can be robust throughout an extended period characterized by constantly evolving conditions, and represent a potentially powerful tool for tackling future pandemic events, particularly for clinical outcome prediction of individual patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CONAHCyT under the Project CF-2023-I-1496, by DGAPA-UNAM under the Projects UNAM-PAPIIT TA101023, UNAM-PAPIIT IN101623, and UNAM-PAPIIT IN103521.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The prospective validation study was conducted using the publicly available database of COVID-19 patients in Mexico. This database, which includes all officially reported confirmed and suspected cases of COVID-19 in Mexico, is available in the Statistical Yearbook of Disease (Anuario Estadisticos de Morbilidad) published by the General Epidemiological Council (Direccion General de Epidemiologia) that is part of the Ministry of Health (Secretaria de Salud) of the Federal Government of Mexico. Data are available in https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicasdireccion-general-de-epidemiologia.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are openly available in the Statistical Morbidity Yearbooks published by the General Council of Epidemiology, part of the Health Ministry, Mexican Federal Government. Data are available in https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicasdireccion-general-de-epidemiologia.